Serina Therapeutics, Inc.
In the quarter to June 2026, revenue grew 2,500.0%, EPS grew 16.7% and free cash flow fell 76.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SER
Serina Therapeutics, Inc. (SER) EV/Sales
As of 16 October 2026, Serina Therapeutics, Inc. (SER) trades at a EV/Sales of 66.0×. Over the past ten years it has ranged from −2.4× (May 2026) to 1,889× (June 2023); the current reading is higher than 33% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 123× | (81.75%) |
| FY2024 | 673× | 6,900.53% |
| FY2023 | 9.6× | (99.16%) |
| FY2022 | 1,148× | 203.16% |
| FY2021 | 379× | 114.01% |
| FY2020 | 177× | 346.78% |
| FY2019 | 39.6× | (45.80%) |
| FY2018 | 73.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2025 | 332× | (50.69%) |
| Dec 2024 | 673× | 3,411.34% |
| Sep 2024 | 19.2× | (15.93%) |
| Jun 2024 | 22.8× | 147.64% |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IBIO iBio, Inc. compare | −9.7× |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| IMA ImageneBio, Inc. compare | 2.5× |
| SER Serina Therapeutics, Inc. | 66.0× |
| INMB INmune Bio, Inc. compare | 210× |
| CLNN Clene Inc. compare | 239× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)